Restraints High Cost and Potential Gastrointestinal Side Effects May Restrain Market Growth The relatively high cost of GLP-1 receptor agonists can be a significant restraint on market growth, particularly in regions with limited healthcare access or reimbursement
41 Likewise, hypotensive events secondary to volume depletion with SGLT-2 inhibitor therapy have been reported
In 2021, AMG133, a bispecific molecule that combines GIP receptor antagonism and GLP-1 receptor agonism was presented
And we humans are notoriously bad at estimating what we eat
A comprehensive analysis of the known effects of GLP-1 and GLP-1RAs on cognitive, cellular, and molecular changes in NDD in preclinical and clinical studies have shown that both natural GLP-1 and its analogues, GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide) improve cognitive and motor functions
The route depends on the primary indication: oral BPC-157 targets the GI tract more directly, while injectable BPC-157 provides systemic distribution for musculoskeletal applications